Pipeline
Autifony’s pipeline includes clinical stage programmes for Schizophrenia and Fragile X, and earlier stage programmes focused on Hearing disorders and Alzheimer’s Disease.
Autifony has been granted Orphan Drug Designation for AUT00206 for the treatment of Fragile X Syndrome.
Therapeutic area
Compound
(Target)
(Target)
Indication
Preclinical
Phase 1
Phase 2
Psychiatry
AUT00206
(Kv3.1/3.2)
(Kv3.1/3.2)
Schizophrenia
Neurology
AUT00206
(Kv3.1/3.2)
(Kv3.1/3.2)
Fragile X
Kv3.1
Hearing disorders
Undisclosed target
Alzheimer’s Disease
Comments are closed.